MA55624A - Composés, compositions et procédés - Google Patents
Composés, compositions et procédésInfo
- Publication number
- MA55624A MA55624A MA055624A MA55624A MA55624A MA 55624 A MA55624 A MA 55624A MA 055624 A MA055624 A MA 055624A MA 55624 A MA55624 A MA 55624A MA 55624 A MA55624 A MA 55624A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832775P | 2019-04-11 | 2019-04-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55624A true MA55624A (fr) | 2022-02-16 |
Family
ID=72752101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055624A MA55624A (fr) | 2019-04-11 | 2020-04-10 | Composés, compositions et procédés |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12358896B2 (fr) |
| EP (1) | EP3953348B1 (fr) |
| JP (1) | JP7623294B2 (fr) |
| KR (1) | KR102962366B1 (fr) |
| CN (1) | CN113939294A (fr) |
| AR (1) | AR118641A1 (fr) |
| AU (1) | AU2020272045B2 (fr) |
| BR (1) | BR112021020027A2 (fr) |
| CA (1) | CA3136447A1 (fr) |
| DK (1) | DK3953348T3 (fr) |
| EA (1) | EA202192530A1 (fr) |
| ES (1) | ES3018383T3 (fr) |
| IL (1) | IL287120B2 (fr) |
| MA (1) | MA55624A (fr) |
| MX (1) | MX2021012392A (fr) |
| SG (1) | SG11202111058XA (fr) |
| TW (1) | TWI851710B (fr) |
| WO (1) | WO2020210684A1 (fr) |
| ZA (1) | ZA202107499B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3086182A1 (fr) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Procede de preparation de composes pyrimidinyl-4-aminopyrazole |
| AU2021371697B2 (en) * | 2020-10-29 | 2024-10-24 | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof |
| CN116120291B (zh) * | 2023-04-11 | 2023-06-30 | 英矽智能科技(上海)有限公司 | 吲唑类化合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101566091B1 (ko) | 2010-11-10 | 2015-11-04 | 에프. 호프만-라 로슈 아게 | Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체 |
| PT3472153T (pt) * | 2016-06-16 | 2021-12-31 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos |
| WO2018217946A1 (fr) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Composés, compositions et procédés |
| CA3086182A1 (fr) | 2017-12-20 | 2019-06-27 | Denali Therapeutics Inc. | Procede de preparation de composes pyrimidinyl-4-aminopyrazole |
-
2020
- 2020-04-08 AR ARP200101008A patent/AR118641A1/es unknown
- 2020-04-10 SG SG11202111058XA patent/SG11202111058XA/en unknown
- 2020-04-10 US US17/602,480 patent/US12358896B2/en active Active
- 2020-04-10 MX MX2021012392A patent/MX2021012392A/es unknown
- 2020-04-10 WO PCT/US2020/027742 patent/WO2020210684A1/fr not_active Ceased
- 2020-04-10 MA MA055624A patent/MA55624A/fr unknown
- 2020-04-10 CN CN202080041217.0A patent/CN113939294A/zh active Pending
- 2020-04-10 DK DK20787582.4T patent/DK3953348T3/da active
- 2020-04-10 JP JP2021559818A patent/JP7623294B2/ja active Active
- 2020-04-10 KR KR1020217036412A patent/KR102962366B1/ko active Active
- 2020-04-10 AU AU2020272045A patent/AU2020272045B2/en active Active
- 2020-04-10 ES ES20787582T patent/ES3018383T3/es active Active
- 2020-04-10 IL IL287120A patent/IL287120B2/en unknown
- 2020-04-10 TW TW109112173A patent/TWI851710B/zh active
- 2020-04-10 BR BR112021020027A patent/BR112021020027A2/pt unknown
- 2020-04-10 EA EA202192530A patent/EA202192530A1/ru unknown
- 2020-04-10 EP EP20787582.4A patent/EP3953348B1/fr active Active
- 2020-04-10 CA CA3136447A patent/CA3136447A1/fr active Pending
-
2021
- 2021-10-05 ZA ZA2021/07499A patent/ZA202107499B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES3018383T3 (es) | 2025-05-16 |
| EP3953348B1 (fr) | 2024-12-18 |
| CN113939294A (zh) | 2022-01-14 |
| AU2020272045A1 (en) | 2021-10-28 |
| IL287120B1 (en) | 2025-02-01 |
| BR112021020027A2 (pt) | 2021-12-07 |
| TWI851710B (zh) | 2024-08-11 |
| JP7623294B2 (ja) | 2025-01-28 |
| DK3953348T3 (da) | 2025-03-17 |
| WO2020210684A1 (fr) | 2020-10-15 |
| JP2022526015A (ja) | 2022-05-20 |
| AR118641A1 (es) | 2021-10-20 |
| KR102962366B1 (ko) | 2026-05-11 |
| TW202104213A (zh) | 2021-02-01 |
| AU2020272045B2 (en) | 2026-01-15 |
| EP3953348A1 (fr) | 2022-02-16 |
| MX2021012392A (es) | 2021-11-12 |
| CA3136447A1 (fr) | 2020-10-15 |
| EA202192530A1 (ru) | 2022-03-15 |
| IL287120B2 (en) | 2025-06-01 |
| US20220220094A1 (en) | 2022-07-14 |
| EP3953348A4 (fr) | 2023-01-18 |
| SG11202111058XA (en) | 2021-11-29 |
| ZA202107499B (en) | 2022-06-29 |
| IL287120A (en) | 2021-12-01 |
| KR20210151887A (ko) | 2021-12-14 |
| US12358896B2 (en) | 2025-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54953A (fr) | Composés, compositions et procédés | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA54946A (fr) | Procédés et composés | |
| MA49858A (fr) | Composés, compositions et procédés | |
| EP3917927A4 (fr) | Immunomodulateurs, compositions et procédés associés | |
| MA50063A (fr) | Composés, compositions et procédés | |
| MA54875A (fr) | Compositions oligonucléotidiques et procédés associés | |
| EP3806906A4 (fr) | Nouveaux composés cétogènes, compositions, procédés et utilisation de ceux-ci | |
| EP3823673A4 (fr) | Compositions anti-cd112r et procédés | |
| MA56032A (fr) | Composés, compositions et procédés d'utilisation | |
| EP3880194A4 (fr) | Composés deutérés, compositions et utilisations | |
| LT4084779T (lt) | 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos | |
| DK3924443T3 (da) | Compositions | |
| MA52896A (fr) | Composés inhibiteurs de vmat2, compositions et méthodes associées | |
| EP3494119A4 (fr) | Composés et compositions, et utilisations associées | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| PL3967726T3 (pl) | Kompozycja utwardzalna | |
| EP3871694A4 (fr) | Composition | |
| EP4077318A4 (fr) | Composés | |
| EP4079787A4 (fr) | Composition durcissable | |
| EP3552017A4 (fr) | Composés, compositions et méthodes | |
| EP3981256A4 (fr) | Composition | |
| EP3954721A4 (fr) | Composition | |
| EP3941942A4 (fr) | Composition | |
| EP3801021A4 (fr) | Procédés et compositions sporicides |